BELANTAMAB MAFODOTIN-BLMF: 150 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
150
Total FAERS Reports
60 (40.0%)
Deaths Reported
36
Hospitalizations
150
As Primary/Secondary Suspect
5
Life-Threatening
1
Disabilities
Prescription
Status
FDA Application: 761440 ·
First Report: 202005 · Latest Report: 20250801
What Are the Most Common BELANTAMAB MAFODOTIN-BLMF Side Effects?
#1 Most Reported
Death
32 reports (21.3%)
#2 Most Reported
Plasma cell myeloma
15 reports (10.0%)
#3 Most Reported
Visual impairment
11 reports (7.3%)
All BELANTAMAB MAFODOTIN-BLMF Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 32 | 21.3% | 32 | 2 |
| Plasma cell myeloma | 15 | 10.0% | 8 | 2 |
| Keratopathy | 11 | 7.3% | 3 | 1 |
| Visual impairment | 11 | 7.3% | 0 | 0 |
| Ocular toxicity | 10 | 6.7% | 0 | 0 |
| Condition aggravated | 9 | 6.0% | 4 | 1 |
| Plasma cell myeloma refractory | 9 | 6.0% | 2 | 1 |
| Disease progression | 7 | 4.7% | 2 | 0 |
| Dry eye | 7 | 4.7% | 0 | 0 |
| Fatigue | 7 | 4.7% | 3 | 2 |
| Visual acuity reduced | 7 | 4.7% | 0 | 0 |
| Corneal disorder | 6 | 4.0% | 1 | 0 |
| Therapy cessation | 6 | 4.0% | 3 | 0 |
| Corneal epithelial microcysts | 5 | 3.3% | 1 | 0 |
| Hypercalcaemia | 5 | 3.3% | 0 | 5 |
| Pyrexia | 5 | 3.3% | 2 | 2 |
| Renal failure | 5 | 3.3% | 2 | 3 |
| Vision blurred | 5 | 3.3% | 1 | 0 |
Who Reports BELANTAMAB MAFODOTIN-BLMF Side Effects? Age & Gender Data
Gender: 48.3% female, 51.7% male. Average age: 65.9 years. Most reports from: US. View detailed demographics →
Is BELANTAMAB MAFODOTIN-BLMF Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2020 | 4 | 1 | 2 |
| 2021 | 31 | 5 | 12 |
| 2022 | 21 | 8 | 4 |
| 2023 | 7 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
| 2025 | 3 | 1 | 3 |
What Is BELANTAMAB MAFODOTIN-BLMF Used For?
| Indication | Reports |
|---|---|
| Plasma cell myeloma | 68 |
| Product used for unknown indication | 64 |
| Plasma cell myeloma refractory | 11 |
BELANTAMAB MAFODOTIN-BLMF vs Alternatives: Which Is Safer?
BELANTAMAB MAFODOTIN-BLMF vs BELATACEPT
BELANTAMAB MAFODOTIN-BLMF vs BELIMUMAB
BELANTAMAB MAFODOTIN-BLMF vs BELINOSTAT
BELANTAMAB MAFODOTIN-BLMF vs BELUMOSUDIL
BELANTAMAB MAFODOTIN-BLMF vs BELVIQ
BELANTAMAB MAFODOTIN-BLMF vs BELZUTIFAN
BELANTAMAB MAFODOTIN-BLMF vs BEMPEDOIC ACID
BELANTAMAB MAFODOTIN-BLMF vs BEMPEDOIC ACID\EZETIMIBE
BELANTAMAB MAFODOTIN-BLMF vs BEMPEGALDESLEUKIN
BELANTAMAB MAFODOTIN-BLMF vs BENADRYL
Official FDA Label for BELANTAMAB MAFODOTIN-BLMF
Official prescribing information from the FDA-approved drug label.